Patents Assigned to ALLOCURE, INC.

Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same

Publication number: 20130129688

Abstract: The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stem cell (MSC) populations by determining the number of GT repeats in the heme oxygenase-1 (HO-1) promoter region of both alleles.

Type: Application

Filed: November 7, 2012

Publication date: May 23, 2013

Applicant: ALLOCURE, INC.

Inventor: Allocure, Inc.
Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same

Publication number: 20120276067

Abstract: The invention relates to assays for testing the therapeutic effectiveness of mesenchymal stromal cell (MSC) populations and methods of treating pathologies with passaged and/or frozen and thawed MSC populations.

Type: Application

Filed: October 13, 2010

Publication date: November 1, 2012

Applicant: Allocure, Inc.

Inventor: Christof Westenfelder
MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME

Publication number: 20120269779

Abstract: The invention relates to mesenchymal stromal cells produced by culturing the cells in platelet lysate supplemented media and methods of using these cells to treat neurological and kidney associated disorders.

Type: Application

Filed: October 29, 2010

Publication date: October 25, 2012

Applicant: ALLOCURE, INC.

Inventor: Christof Westenfelder
Methods of Using SDF-1 (CXCL12) as a Diagnostic and Mesenchymal Stem Cell (Multipotent Stromal Cell)-Specific Therapeutic Biomarker for the Treatment of Kidney Injury and Other Major Organs

Publication number: 20110259350

Abstract: This application describes the detection and diagnosis of kidney pathology including acute kidney injury by the detection of changes in the amounts of biomarkers in the urine of patients. These biomarkers include stromal derived factor (SDF-1 or CXCL12).

Type: Application

Filed: October 22, 2009

Publication date: October 27, 2011

Applicant: ALLOCURE, INC.

Inventor: Christof Westenfelder

Assay for the Prediction of Therapeutic Effectiveness or Potency of Mesenchymal Stem Cells, and Methods of Using Same

Assay for the Prediction of Therapeutic Effectiveness of Mesenchymal Stromal Cells, and Methods of Using Same

MESENCHYMAL STROMAL CELL POPULATIONS AND METHODS OF USING SAME

Methods of Using SDF-1 (CXCL12) as a Diagnostic and Mesenchymal Stem Cell (Multipotent Stromal Cell)-Specific Therapeutic Biomarker for the Treatment of Kidney Injury and Other Major Organs